Medicare drug price negotiation under the Inflation Reduction Act (IRA) is no longer theoretical—it is operational and already reshaping the Medicare drug landscape. This session will examine how the first year of negotiated pricing in Medicare Part D is playing out, including what has worked as intended, what has surprised stakeholders, and where operational and financial challenges remain.
Building on those lessons, the session will review the drugs selected for 2027 and look ahead to 2028, when negotiated pricing expands to include Medicare Part B–administered drugs. Attendees will gain insight into the policy, financial, and operational implications of this next phase and explore practical considerations for providers as they prepare for continued implementation and downstream impacts. This session is designed for both strategic leaders and operational stakeholders seeking to stay ahead of evolving Medicare drug pricing policy.
Assess the real-world impacts of the Inflation Reduction Act following the first year of Medicare Part D drug price negotiation, including effects on provider cash flow, the two-tier payment structure, interactions with the 340B program, and patient out-of-pocket costs.
Evaluate potential downstream implications of Medicare drug price negotiation on commercial payer contracting, including impacts on drug reimbursement benchmarks such as ASP, AWP, and WAC.
.jpg)
